196 related articles for article (PubMed ID: 35788405)
41. Precious Gene: The Application of RET-Altered Inhibitors.
Gou Q; Gan X; Li L; Gou Q; Zhang T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971
[TBL] [Abstract][Full Text] [Related]
42. An early look at selective RET inhibitor resistance: new challenges and opportunities.
Lin JJ; Gainor JF
Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.
Ali MA; Shah SS; Ali R; Bajwa SF; Rehman S; Anwar A; Anwar MY; Saeed M; Mirza N; Aiman W
Cancer Invest; 2023 Sep; 41(8):739-749. PubMed ID: 37782113
[TBL] [Abstract][Full Text] [Related]
44. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
45. The lipoprotein profile of chylous and nonchylous pleural effusions.
Staats BA; Ellefson RD; Budahn LL; Dines DE; Prakash UB; Offord K
Mayo Clin Proc; 1980 Nov; 55(11):700-4. PubMed ID: 7442324
[TBL] [Abstract][Full Text] [Related]
46. Recurrent Chylous Ascites Leading to Transudative Chylothorax Due to Bi-Ventricular Heart Failure.
Do TVC; Cozza J; Ganti S; Depa J
J Investig Med High Impact Case Rep; 2021; 9():23247096211026144. PubMed ID: 34148400
[TBL] [Abstract][Full Text] [Related]
47. Outcome of neonatal chylous effusions: what do you tell the parents? A 10-year experience in a community hospital.
Bengtsson BO
Am J Perinatol; 2014 Dec; 31(12):1037-42. PubMed ID: 24566754
[TBL] [Abstract][Full Text] [Related]
48. Diagnosis of chylous abdominal effusions: what is the triglyceride threshold value?
Lefrère B; Curis E; Bittar R; Levasseur A; Grès P; Guilbert Z; Zenati B; Cherfils C; Sakka M; Bonnefont-Rousselot D
Biochem Med (Zagreb); 2023 Jun; 33(2):020902. PubMed ID: 37143714
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia.
Kelly RL; Bae JY; D'Annunzio S; Montanari F
Am J Case Rep; 2022 Nov; 23():e938319. PubMed ID: 36444127
[TBL] [Abstract][Full Text] [Related]
50. Percutaneous Balloon Plasty for Thoracic Duct Occlusion in a Patient with Chylothorax and Chylous Ascites.
Kariya S; Nakatani M; Ono Y; Maruyama T; Ueno Y; Komemushi A; Tanigawa N
Cardiovasc Intervent Radiol; 2019 May; 42(5):779-783. PubMed ID: 30617452
[TBL] [Abstract][Full Text] [Related]
51. Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for
Bajaj S; Chow A; Drilon A; Kalchiem-Dekel O
JTO Clin Res Rep; 2023 Dec; 4(12):100606. PubMed ID: 38162174
[TBL] [Abstract][Full Text] [Related]
52. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
[TBL] [Abstract][Full Text] [Related]
53. Chylothorax and chylous ascites: Overview, management, and nutrition.
Duletzke NT; Kiraly LN; Martindale RG
Nutr Clin Pract; 2023 Jun; 38(3):557-563. PubMed ID: 36938719
[TBL] [Abstract][Full Text] [Related]
54. Drug resistance profiles of mutations in the RET kinase domain.
Liu X; Shen T; Mooers BHM; Hilberg F; Wu J
Br J Pharmacol; 2018 Sep; 175(17):3504-3515. PubMed ID: 29908090
[TBL] [Abstract][Full Text] [Related]
55. Chylothorax and chylous ascites. Clinical utility of planar scintigraphy and tomographic imaging with SPECT/CT.
Weiss M; Schwarz F; Wallmichrath J; Baumeister R; Frick A; Bartenstein P; Rominger A
Nuklearmedizin; 2015; 54(5):231-40. PubMed ID: 26183818
[TBL] [Abstract][Full Text] [Related]
56. Chylous ascites and chylothorax as presenting manifestations of stomach carcinoma.
Segal R; Waron M; Reif R; Zecler E
Isr J Med Sci; 1986 Dec; 22(12):897-9. PubMed ID: 3570735
[TBL] [Abstract][Full Text] [Related]
57. [A clinical analysis of neonatal chylous effusions].
Lu DF; Tong XM
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Apr; 22(4):328-333. PubMed ID: 32312370
[TBL] [Abstract][Full Text] [Related]
58. Chylothorax and chylous ascites in a patient with uterine cancer.
Tani K; Ogushi F; Sone S; Kagawa N; Ogura T
Jpn J Clin Oncol; 1988 Jun; 18(2):175-82. PubMed ID: 3288782
[TBL] [Abstract][Full Text] [Related]
59. [Post-surgical lymphocutaneous fistula, chylous ascites and chylothorax--infrequent but serious complications: etiology, diagnosis and therapeutic options].
Benedix F; Lippert H; Meyer F
Zentralbl Chir; 2007 Dec; 132(6):529-38. PubMed ID: 18098081
[TBL] [Abstract][Full Text] [Related]
60. A case of gallbladder cancer manifesting chylous ascites and chylothorax.
Shiina S; Ohshima M; Fujino H; Muto H; Yasuda H; Kawabe T; Tagawa K; Unuma T; Ibukuro K; Inoue Y
Gastroenterol Jpn; 1989 Apr; 24(2):209-13. PubMed ID: 2744338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
